Advertisement

Digestive Diseases and Sciences

, Volume 63, Issue 10, pp 2695–2702 | Cite as

A Study of Optimal Screening for Latent Tuberculosis in Patients with Inflammatory Bowel Disease

  • Talal Al-Taweel
  • Matthew Strohl
  • Madhukar Pai
  • Myriam Martel
  • Talat Bessissow
  • Alain Bitton
  • Ernest Seidman
  • Waqqas Afif
Original Article
  • 145 Downloads

Abstract

Background

Reactivation of LTBI in patients with IBD on anti-TNF-α agents can lead to serious life-threatening illness. No gold standard exists for the detection of LTBI. We examined whether a dual testing strategy with TST and IGRA would improve the detection of LTBI.

Methods

Consecutive IBD patients being considered for anti-TNF-α treatment underwent testing with a TST, IGRA and CXR. All patients completed a self-administered questionnaire. The association of both tests with demographic factors, LTBI risk factors, BCG vaccination, IS therapy and agreement between the TST and IGRA were evaluated.

Results

One-hundred and fifty-five IBD patients were included, 6% were TST positive and 5% were IGRA positive. Concordance between TST and IGRA was fair (κ = 0.21, 95% CI − 0.081–0.498). Neither test was affected by age, gender or BCG vaccination. The presence of risk factors for LTBI was found to be positively associated with TST (OR 19.8, 95% CI 3.9–102.1), but not IGRA. IGRA was negatively associated with IS therapy (OR 0.06, 95% CI 0.007–0.5), but not TST. Four patients who were IGRA positive but TST negative were treated for LTBI by a respirologist.

Conclusion

An IGRA result was negatively associated with IS therapy, while the presence of risk factors for LTBI was found to be positively associated with TST results. There was fair agreement between positive TST and IGRA results. The addition of IGRA to the standard practice of TST and CXR increased the number of cases that were initiated on LTBI therapy.

Keywords

Latent tuberculosis Anti-tumor necrosis alpha Tuberculin skin test Interferon-gamma release assay 

Abbreviations

IBD

Inflammatory bowel disease

Anti-TNF-α

Anti-tumor necrosis factor alpha

LTBI

Latent Tuberculosis infection

TST

Tuberculin skin test

IGRA

Interferon-gamma release assay

CXR

Chest radiograph

BCG

Bacillus Calmette–Guerin

IS

Immunosuppressive/immunosuppression

Notes

Author’s contribution

TA and WA conceived the study. TA, TB, AB, ES and WA coordinated data collection at their respective sites. TA and MS collected the data. TA, MM and WA aggregated the data and performed analysis. TA wrote the initial draft of the manuscript. TA and WA coordinated revision of the manuscript as guided by all the authors who approved the final version of the manuscript.

Funding

The study was funded by an academic peer-reviewed grant through the Future Leaders in IBD (FLIBD) program, which was administered through Mount Sinai Hospital in Toronto, Canada. Neither FLIBD nor Mount Sinai Hospital had any role in the design or conduct of the study, the interpretation of results, or the development of this manuscript.

Compliance with ethical standards

Conflict of Interest

T Al-Taweel has received travel/accommodation/meeting expenses from Abbvie, Janssen, Newbridge and Novartis, lecture fees from Janssen and Abbvie and consulting fees from Abbvie and Takeda. A. Bitton has received research financial support from Abbvie, lecture fees from Abbvie, Janssen and Shire and consulting fees from Abbvie, Janssen, Shire, Ferring and Takeda. W. Afif has received consulting fees from Abbvie, Janssen, Shire, Ferring and Takeda. T. Bessissow has received research financial support from Abbvie, lecture fees from Abbvie, Janssen, Takeda, Shire, Actavis and Ferring and consultancy fees from Abbvie, Janssen, Takeda, Shire and Actavis. The remaining authors have no conflicts of interest to disclose.

Guarantor of Article

T Al-Taweel MBChB, KMSC, MRCP(UK), MRCPS(Glasg).

References

  1. 1.
    Toruner M, Loftus EV Jr, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008;134:929–936.CrossRefPubMedGoogle Scholar
  2. 2.
    Aberra FN, Stettler N, Brensinger C, et al. Risk for active tuberculosis in inflammatory bowel disease patients. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2007;5:1070–1075.Google Scholar
  3. 3.
    Gomez-Reino JJ, Carmona L, Valverde VR, et al. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: A multicenter active-surveillance report. Arthr Rheum. 2003;48:2122–2127.CrossRefGoogle Scholar
  4. 4.
    Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001;345:1098–1104.CrossRefPubMedGoogle Scholar
  5. 5.
    Menzies D, Pai M, Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med. 2007;146:340–354.CrossRefPubMedGoogle Scholar
  6. 6.
    Pai M, Riley LW, Colford JM Jr. Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review. Lancet Infect Dis. 2004;4:761–776.CrossRefPubMedGoogle Scholar
  7. 7.
    Pai M, Denkinger CM, Kik SV, et al. Gamma interferon release assays for detection of mycobacterium tuberculosis infection. Clin Microbiol Rev. 2014;27:3–20.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Centre for Communicable D, Infection C, Association CL, et al. Canadian Tuberculosis Standards (7th Edition): Public Health Agency of Canada, 2014.Google Scholar
  9. 9.
    Andrisani G, Armuzzi A, Papa A, et al. Comparison of Quantiferon-TB Gold versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease patients. J Gastrointestin Liver Dis. 2013;22:21–25.PubMedGoogle Scholar
  10. 10.
    Papay P, Eser A, Winkler S, et al. Factors impacting the results of interferon-gamma release assay and tuberculin skin test in routine screening for latent tuberculosis in patients with inflammatory bowel diseases. Inflamm Bowel Dis. 2011;17:84–90.CrossRefPubMedGoogle Scholar
  11. 11.
    Qumseya BJ, Ananthakrishnan AN, Skaros S, et al. QuantiFERON TB gold testing for tuberculosis screening in an inflammatory bowel disease cohort in the United States. Inflamm Bowel Dis. 2011;17:77–83.CrossRefPubMedGoogle Scholar
  12. 12.
    Schoepfer AM, Flogerzi B, Fallegger S, et al. Comparison of interferon-gamma release assay versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease. Am J Gastroenterol. 2008;103:2799–2806.CrossRefPubMedGoogle Scholar
  13. 13.
    Shahidi N, Fu YT, Qian H, et al. Performance of interferon-gamma release assays in patients with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis. 2012;18:2034–2042.CrossRefPubMedGoogle Scholar
  14. 14.
    Rahier JF, Magro F, Abreu C, et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohn’s Colitis. 2014;8:443–468.CrossRefGoogle Scholar
  15. 15.
    Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement. Am J Respir Crit Care Med. 2000;161:S221–S247.Google Scholar
  16. 16.
    WHO. Global tuberculosis report 2016: World Health Organization, Geneva, 2016.Google Scholar
  17. 17.
    Agudo B, Díaz G, González-Lama Y. Adalimumab-receiving ulcerative colitis patient suffered latent tuberculosis reactivation despite correct chemoprophylaxis and was successfully treated while on anti-tumour necrosis factor therapy. J Crohn’s Colitis. 2016;10:1453–1454.CrossRefGoogle Scholar
  18. 18.
    de Jong MJ, Roosen D, van Tubergen A. The prevalence of latent tuberculosis and hepatitis B after systematic screening of patients prescribed biological therapy in a low-endemic area. J Crohn’s Colitis. 2018;12:124–125.CrossRefGoogle Scholar
  19. 19.
    Nguyen D, Menzies D. Diagnosis and treatment of latent TB infection. Can J CME. 2001;1:89–97.Google Scholar
  20. 20.
    Choi JC, Shin JW, Kim JY, et al. The effect of previous tuberculin skin test on the follow-up examination of whole-blood interferon-gamma assay in the screening for latent tuberculosis infection. Chest. 2008;133:1415–1420.CrossRefPubMedGoogle Scholar
  21. 21.
    van Zyl-Smit RN, Pai M, Peprah K, et al. Within-subject variability and boosting of T-cell interferon-gamma responses after tuberculin skin testing. Am J Respir Crit Care Med. 2009;180:49–58.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Haya Al-Habeeb Gastroenterology CenterMubarak Al-Kabeer HospitalJabriya, HawallyKuwait
  2. 2.Division of GastroenterologyMcGill University Health CentreMontrealCanada
  3. 3.Department of Epidemiology and BiostatisticsMcGill UniversityMontrealCanada

Personalised recommendations